相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Notch3-Specific Inhibition Using siRNA Knockdown or GSI Sensitizes Paclitaxel-Resistant Ovarian Cancer Cells
Haeyoun Kang et al.
MOLECULAR CARCINOGENESIS (2016)
Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers
Denis Lane et al.
BMC CANCER (2015)
A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer
M. Koti et al.
BRITISH JOURNAL OF CANCER (2015)
Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules
Yu Yu et al.
CANCER CELL (2015)
TP53 hot spot mutations in ovarian cancer: Selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas
Brandon-Luke L. Seagle et al.
GYNECOLOGIC ONCOLOGY (2015)
Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma
Dag Andre Nymoen et al.
GYNECOLOGIC ONCOLOGY (2015)
The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells
Ryan Charles Pink et al.
GYNECOLOGIC ONCOLOGY (2015)
Elevated AKAP12 in Paclitaxel-Resistant Serous Ovarian Cancer Cells Is Prognostic and Predictive of Poor Survival in Patients
Nicholas W. Bateman et al.
JOURNAL OF PROTEOME RESEARCH (2015)
CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma
Dag Andre Nymoen et al.
MOLECULAR CANCER (2015)
A Novel Neutralizing Antibody Targeting Pregnancy-Associated Plasma Protein-A Inhibits Ovarian Cancer Growth and Ascites Accumulation in Patient Mouse Tumorgrafts
Marc A. Becker et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Whole-genome characterization of chemoresistant ovarian cancer
Ann-Marie Patch et al.
NATURE (2015)
Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells
Amit Kumar Srivastava et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
VAV3 Overexpressed in Cancer Stem Cells Is a Poor Prognostic Indicator in Ovarian Cancer Patients
Ah-Young Kwon et al.
STEM CELLS AND DEVELOPMENT (2015)
DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma
Noriko Yamaguchi et al.
TUMOR BIOLOGY (2015)
An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer
D. M. Janzen et al.
NATURE COMMUNICATIONS (2015)
Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer
Tiyasha H. Ayub et al.
ONCOTARGET (2015)
Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal
Abhishek D. Garg et al.
ONCOTARGET (2015)
Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis
Roland F. Schwarz et al.
PLOS MEDICINE (2015)
Harnessing pandemonium: the clinical implications of tumor heterogeneity in ovarian cancer
Sarah P. Blagden
FRONTIERS IN ONCOLOGY (2015)
Notch3 Overexpression Promotes Anoikis Resistance in Epithelial Ovarian Cancer via Upregulation of COL4A2
Caitlin W. Brown et al.
MOLECULAR CANCER RESEARCH (2015)
Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden
Khalid Abubaker et al.
BMC CANCER (2014)
Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes
P-N Teng et al.
BRITISH JOURNAL OF CANCER (2014)
X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary
M. Miyamoto et al.
BRITISH JOURNAL OF CANCER (2014)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition
Benoit Thibault et al.
CANCER AND METASTASIS REVIEWS (2014)
Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer
Pierre-Emmanuel Colombo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions
Ana Slipicevic et al.
GYNECOLOGIC ONCOLOGY (2014)
Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer
N. G. Alkema et al.
GYNECOLOGIC ONCOLOGY (2014)
Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma
Samantha Cohen et al.
GYNECOLOGIC ONCOLOGY (2014)
The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer
John K. Chan et al.
GYNECOLOGIC ONCOLOGY (2014)
Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma
Zhiqun Tang et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
ALDH1A1 Maintains Ovarian Cancer Stem Cell-Like Properties by Altered Regulation of Cell Cycle Checkpoint and DNA Repair Network Signaling
Erhong Meng et al.
PLOS ONE (2014)
microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition
Aditya Parikh et al.
NATURE COMMUNICATIONS (2014)
Notch3 Interactome Analysis Identified WWP2 as a Negative Regulator of Notch3 Signaling in Ovarian Cancer
Jin-Gyoung Jung et al.
PLOS GENETICS (2014)
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers
Johnathan A. Watkins et al.
BREAST CANCER RESEARCH (2014)
Lung Resistance-Related Protein (LRP) Expression in Malignant Ascitic Cells as a Prognostic Marker for Advanced Ovarian Serous Carcinoma
Elizabeth H. Kerr et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Low expression of the X-linked ribosomal protein S4 in human serous epithelial ovarian cancer is associated with a poor prognosis
Serges P. Tsofack et al.
BMC CANCER (2013)
Identification of the IGF1/PI3K/NFκB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer
Madhuri Koti et al.
BMC CANCER (2013)
Prognostic impact of tumor infiltrating CD8+T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium
Anna Bachmayr-Heyda et al.
BMC CANCER (2013)
Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer
J. H. Huh et al.
BRITISH JOURNAL OF CANCER (2013)
Validated gene targets associated with curatively treated advanced serous ovarian carcinoma
Joyce N. Barlin et al.
GYNECOLOGIC ONCOLOGY (2013)
Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance
Thea Eline Hetland et al.
HUMAN PATHOLOGY (2013)
Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases
Olga Vaksman et al.
HUMAN PATHOLOGY (2013)
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
Louise J. Barber et al.
JOURNAL OF PATHOLOGY (2013)
Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling
Ali Bashashati et al.
JOURNAL OF PATHOLOGY (2013)
Role of Focal Adhesion Kinase in Regulating YB-1-Mediated Paclitaxel Resistance in Ovarian Cancer
Yu Kang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
miR-9 Regulation of BRCA1 and Ovarian Cancer Sensitivity to Cisplatin and PARP Inhibition
Chaoyang Sun et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Identification of Ovarian Cancer Metastatic miRNAs
Souriya Vang et al.
PLOS ONE (2013)
Human Omental-Derived Adipose Stem Cells Increase Ovarian Cancer Proliferation, Migration, and Chemoresistance
Aleksandra Nowicka et al.
PLOS ONE (2013)
A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis
Andrea Vecchione et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Evaluating cell lines as tumour models by comparison of genomic profiles
Silvia Domcke et al.
NATURE COMMUNICATIONS (2013)
Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research
Nuzhat Ahmed et al.
FRONTIERS IN ONCOLOGY (2013)
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
V. Abkevich et al.
BRITISH JOURNAL OF CANCER (2012)
LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin
Prue A. Cowin et al.
CANCER RESEARCH (2012)
CD44+/CD24-ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival
Erhong Meng et al.
CLINICAL & EXPERIMENTAL METASTASIS (2012)
Multidrug Resistance-Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma
Jean-Pierre Gillet et al.
CLINICAL CANCER RESEARCH (2012)
Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome
Zhigang C. Wang et al.
CLINICAL CANCER RESEARCH (2012)
Elevated expression of astrocyte elevated gene-1 (AEG-1) is correlated with cisplatin-based chemoresistance and shortened outcome in patients with stages III-IV serous ovarian carcinoma
Cong Li et al.
HISTOPATHOLOGY (2012)
Spectrin αII and βII tetramers contribute to platinum anticancer drug resistance in ovarian serous adenocarcinoma
Osamu Maeda et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Kathryn Alsop et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer
Fiona Furlong et al.
JOURNAL OF PATHOLOGY (2012)
Isolation and Characterization of Tumor Cells from the Ascites of Ovarian Cancer Patients: Molecular Phenotype of Chemoresistant Ovarian Tumors
Ardian Latifi et al.
PLOS ONE (2012)
Screening and Identification of Biomarkers in Ascites Related to Intrinsic Chemoresistance of Serous Epithelial Ovarian Cancers
He Huang et al.
PLOS ONE (2012)
Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features
Jaime Prat
VIRCHOWS ARCHIV (2012)
Co-expression of VEGF and CA9 in ovarian high-grade serous carcinoma and relationship to survival
Emma Williams et al.
VIRCHOWS ARCHIV (2012)
Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
Nicolai J. Birkbak et al.
CANCER DISCOVERY (2012)
HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer
Euan A. Stronach et al.
CANCER RESEARCH (2011)
The Biphasic Role of NF-κB in Progression and Chemoresistance of Ovarian Cancer
Gong Yang et al.
CLINICAL CANCER RESEARCH (2011)
Genomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas
David S. P. Tan et al.
CLINICAL CANCER RESEARCH (2011)
BAD Phosphorylation Determines Ovarian Cancer Chemosensitivity and Patient Survival
Douglas C. Marchion et al.
CLINICAL CANCER RESEARCH (2011)
Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance
Thea Eline Hetland et al.
HUMAN PATHOLOGY (2011)
Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior
Belen Canet et al.
HUMAN PATHOLOGY (2011)
Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer
Da Yang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
Barbara Norquist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma
Ie-Ming Shih et al.
MODERN PATHOLOGY (2011)
Ovarian Cancer Stem Cell-Like Side Populations Are Enriched Following Chemotherapy and Overexpress EZH2
Sian Rizzo et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Clinical Relevance of Multidrug Resistance Gene Expression in Ovarian Serous Carcinoma Effusions
Jean-Pierre Gillett et al.
MOLECULAR PHARMACEUTICS (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance
Jean-Pierre Gillet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy
Hans Boesmueller et al.
VIRCHOWS ARCHIV (2011)
Notch3 Overexpression Is Related to the Recurrence of Ovarian Cancer and Confers Resistance to Carboplatin
Joon Tae Park et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Foxp3+ cell infiltration and granzyme B+/Foxp3+ cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma
Martin Poelcher et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer
Alain G. Zeimet et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma
C. Blake Gilks et al.
HUMAN PATHOLOGY (2008)
A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival
Kentaro Nakayama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
分享论文
